Clinical Trial: Anti-pd-1 /CTLA-4 double immune combination antibody reverses the resistance of PD-1 -(L)1 monoclonal antibody by targeting Macro-C1Q in cervical cancer (China)

China, Sept. 9 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Anti-pd-1 /CTLA-4 double immune combination antibody reverses the resistance of PD-1 -(L)1 monoclonal antibody by targeting Macro-C1Q in cervical cancer'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600131941

Registration Time: 2026/09/08

Type: Interventional study

Primary Sponsor: The 2nd Affiliated Hospital of Chongqing Medical University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=337794

Published by HT Digital Content Services with permission from Health Daily Digest....